8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements

AbbVie ($ABBV) issued a press release on Feb 4, 2026 announcing Q4 & FY 2025 financial results.

Filed with the SEC on February 4, 2026 · Summarized by InvestorsBot

AbbVie ($ABBV) issued a press release on Feb 4, 2026 announcing Q4 & FY 2025 financial results. The release is furnished as Exhibit 99.1 to the 8‑K — investors should review it for full metrics and commentary. 📊 #earnings #SECfiling

8‑K Item 2.02 filed 02/04/2026: AbbVie furnished its Q4 & FY2025 results press release as Exhibit 99.1. Check SEC EDGAR or the company site for Exhibit 99.1 to see revenue, EPS, guidance and management remarks. 🔍 $ABBV #SECfiling #investing

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from AbbVie Inc.

AbbVie 8-K (Item 9.01) — Supplemental Indenture No.

8-K · March 4, 2026

On Mar 4, 2026 AbbVie completed an $8.0B notes offering: $750M floating-rate due 2028; $1.5B 3.775% due…

8-K · March 4, 2026

AbbVie ($ABBV) filed Form 8‑K (Item 9.01) attaching an Underwriting Agreement dated Feb 24, 2026 among…

8-K · February 26, 2026

AbbVie ($ABBV) 2/24/26 agreed to sell $8.0B of senior notes across seven tranches (2028–2066); pricing…

8-K · February 26, 2026

AbbVie files Form 8‑K dated Feb 4, 2026: furnishes press release (Exhibit 99.1) pursuant to Item 2.02;…

8-K · February 4, 2026

AbbVie filed an 8‑K on Jan 7, 2026.

8-K · January 7, 2026